Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:03:40.358Z.
Calculation as of: 2026-10-06T20:03:40.358Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a3ccde1bd0df5c55ebc0148063105fff0bf751cb52a3071af3e3331f6001fbe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$500.52M
EBITDA Yield
9.38%
TTM Avg
6.87%
3Y Avg
8.16%
5Y Avg
6.43%
Market Cap
$502.81M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$483.54M
EBITDA Yield
9.61%
TTM Avg
13.75%
3Y Avg
18.95%
5Y Avg
18.84%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $498.52M | N/A | N/A | N/A | N/A |
| Tactile Systems Technology, Inc. (TCMD)vs › | $500.52M | 9.38% | 6.87% | 8.16% | 6.43% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $502.81M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.93M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.04M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $505.87M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $486.01M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 9.61% | 13.75% | 18.95% | 18.84% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
